Enhanced genetic modification of adult growth factor mobilized peripheral blood hematopoietic stem and progenitor cells with rapamycin

Stem Cells Translational Medicine

Volumn 3, Issue 10, 2014, Pages 1199-1208

  Li, Lijing ^a   Torres Coronado, Mónica ^a   Gu, Angel ^a   Rao, Anitha ^a   Gardner, Agnes M ^a   Epps, Elizabeth W ^a   Gonzalez, Nancy ^a   Tran, Chy Anh ^b   Wu, Xiwei ^a   Wang, Jin Hui ^a   DiGiusto, David L ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b Centre for Blood Cell Therapies at Peter McCallum Center   (Australia)

Author keywords

Genetic; Hematopoietic stem cells; HIV; Mice; SCID; Sirolimus; Transduction; Transplantation

Indexed keywords

APOLIPOPROTEIN B; CD14 ANTIGEN; CD15 ANTIGEN; CD33 ANTIGEN; CD34 ANTIGEN; FLT3 LIGAND; GREEN FLUORESCENT PROTEIN; INTERLEUKIN 6; RAPAMYCIN; STEM CELL FACTOR; THROMBOPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL VIABILITY; COLONY FORMING UNIT; CONTROLLED STUDY; COPY NUMBER VARIATION; DNA MODIFICATION; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HEMATOPOIETIC STEM CELL; LENTIVIRINAE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; STEM CELL MOBILIZATION; VIRAL GENE DELIVERY SYSTEM; ANIMAL; CELL CULTURE TECHNIQUE; DRUG EFFECTS; GENE THERAPY; GENE VECTOR; GENETIC TRANSDUCTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IN VITRO STUDY; NONOBESE DIABETIC MOUSE; PROCEDURES;

MUS;

ANIMALS; CELL CULTURE TECHNIQUES; FLOW CYTOMETRY; GENETIC THERAPY; GENETIC VECTORS; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; IN VITRO TECHNIQUES; LENTIVIRUS; MICE; MICE, INBRED NOD; POLYMERASE CHAIN REACTION; SIROLIMUS; TRANSDUCTION, GENETIC;

EID: 84908054283     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2014-0010     Document Type: Article

References (43)

1. Cartier N, Hacein-Bey-Abina S, Bartholomae CC et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 2009;326:818-823.
2. Cavazzana-CalvoM,Payen E, NegreOet al. Transfusion independence and HMGA2 activation after gene therapy of human b-thalassaemia. Nature 2010;467:318-322.
3. Aiuti A, Biasco L, Scaramuzza S et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science 2013;341:1233151.
4. Biffi A, Montini E, Lorioli L et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 2013; 341:1233158.
5. Li MJ, Kim J, Li S et al. Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy. Mol Ther 2005;12:900-909.
6. DiGiusto DL, Krishnan A, Li L et al. RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDSrelated lymphoma. Sci Transl Med 2010;2: 36ra43.
7. DiGiusto DL, Stan R, Krishnan A et al. Development of hematopoietic stem cell based gene therapy for HIV-1 infection: Considerations for proof of concept studies and translation to standard medical practice. Viruses 2013;5:2898-2919.
8. Millington M, Arndt A, Boyd M et al. Towards a clinically relevant lentiviral transduction protocol for primary humanCD34hematopoietic stem/progenitor cells. PLoS One 2009;4:e6461.
9. Lee HJ, Lee YS, Kim HS et al. Retronectin enhances lentivirus-mediated gene delivery into hematopoietic progenitor cells. Biologicals 2009;37:203-209.
10. Liu Y, Hangoc G, Campbell TB et al. Identification of parameters required for efficient lentiviral vector transduction and engraftment of human cord blood CD34(+) NOD/SCIDrepopulating cells. Exp Hematol 2008;36:947- 956.
11. Davis BM, Humeau L, Slepushkin V et al. ABC transporter inhibitors that are substrates enhance lentiviral vector transduction into primitive hematopoietic progenitor cells. Blood 2004;104:364-373.
12. Donahue RE, Sorrentino BP, Hawley RG et al. Fibronectin fragment CH-296 inhibits apoptosis and enhances ex vivo gene transfer by murine retrovirus and human lentivirus vectors independent of viral tropism in nonhuman primate CD34+ cells. Mol Ther 2001;3: 359-367.
13. Haas DL, Case SS, CrooksGMet al. Critical factors influencing stable transduction of human CD34(+) cells with HIV-1-derived lentiviral vectors. Mol Ther 2000;2:71-80.
14. Wang CX, Sather BD, Wang X et al. Rapamycin relieves lentiviral vector transduction resistance in human and mouse hematopoietic stem cells. Blood 2014 [Epub ahead of print].
15. Menendez JA, Vellon L, Oliveras-Ferraros C et al. mTOR-regulated senescence and autophagy during reprogramming of somatic cells to pluripotency: A roadmap from energy metabolism to stem cell renewal and aging. Cell Cycle 2011;10:3658-3677.
16. Jung CH, Ro SH, Cao J et al. mTOR regulation of autophagy. FEBS Lett 2010;584:1287- 1295.
17. Webster AC, Lee VW, Chapman JR et al. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: A systematic review and meta-analysis of randomized trials. Transplantation 2006;81:1234-1248.
18. Sehgal SN.Rapamune(RAPA, rapamycin, sirolimus): Mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998;31:335-340.
19. Grube E, Buellesfeld L. Rapamycin analogs for stent-based local drug delivery. Everolimus- and tacrolimus-eluting stents. Herz 2004;29:162-166.
20. Holdaas H, Midtvedt K, Åsberg A. A drug safety evaluation of everolimus in kidney transplantation. Expert Opin Drug Saf 2012;11: 1013-1022.
21. Nguyen SA, Walker D, Gillespie MB et al. mTOR inhibitors and its role in the treatment of head and neck squamous cell carcinoma. Curr Treat Options Oncol 2012;13:71-81.
22. Voss MH, Molina AM, Motzer RJ. mTOR inhibitors in advanced renal cell carcinoma. Hematol Oncol Clin North Am 2011;25:835- 852.
23. Abouelnasr A, Roy J, Cohen S et al. Defining the role of sirolimus in the management of graft-versus-host disease: From prophylaxis to treatment. Biol Blood Marrow Transplant 2013; 19:12-21.
24. Rohrabaugh SL, Campbell TB, Hangoc G et al. Ex vivo rapamycin treatment of human cord blood CD34+ cells enhances their engraftment of NSG mice. Blood Cells Mol Dis 2011;46: 318-320.
25. Chung J, Scherer LJ, Gu A et al. Optimized vectors for HIV gene therapy: Multiplexed expression of small RNAs and inclusion of MGMT (P140K) drug resistance gene. Mol Ther 2014; 22:952-963.
26. Escarpe P, Zayek N, Chin P et al. Development of a sensitive assay for detection of replication-competent recombinant lentivirus in large-scale HIV-based vector preparations. Mol Ther 2003;8:332-341.
27. Manilla P, Rebello T, Afable C et al. Regulatory considerations for novel gene therapy products: A review of the process leading to the first clinical lentiviral vector.HumGeneTher 2005;16:17-25.
28. Sastry L, Xu Y, Johnson T et al. Certification assays for HIV-1-based vectors: Frequent passage of gag sequences without evidence of replication-competent viruses. Mol Ther 2003; 8:830-839.
29. Trobridge GD, Beard BC, Gooch C et al. Efficient transduction of pigtailed macaque hematopoietic repopulating cells with HIVbased lentiviral vectors. Blood 2008;111:5537- 5543.
30. Beard BC, Trobridge GD, Ironside C et al. Efficient and stable MGMT-mediated selection of long-term repopulating stem cells in nonhuman primates. J Clin Invest 2010;120:2345- 2354.
31. Boitano AE, Wang J, Romeo R et al. Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science 2010;329:1345-1348.
32. Li L, Krymskaya L, Wang J et al. Genomic editing of the HIV-1 coreceptor CCR5 in adult hematopoietic stem and progenitor cells using zinc finger nucleases. Mol Ther 2013;21:1259- 1269.
33. National Research Council. Guide for the Care and Use of Laboratory Animals. 8th ed. Washington, D.C.: The National Academies Press, 2011.
34. Tran CA, Torres-Coronado M, Gardner A et al. Optimized processing of growth factor mobilized peripheral blood CD34+ products by counterflow centrifugal elutriation. STEM CELLS TRANSLATIONAL MEDICINE 2012;1:422- 429.
35. Baum CM, Weissman IL, Tsukamoto AS et al. Isolation of a candidate human hematopoietic stem-cell population. Proc Natl Acad Sci USA 1992;89:2804-2808.
36. Notta F, Doulatov S, Laurenti E et al. Isolation of single human hematopoietic stem cells capable of long-termmultilineage engraftment. Science 2011;333:218-221.
37. Lee CI, Kohn DB, Ekert JE et al. Morphological analysis and lentiviral transduction of fetal monkey bone marrow-derived mesenchymal stem cells. Mol Ther 2004;9:112-123.
38. Nayak SK, McCallister T, Han LJ et al. Transduction of human renal carcinoma cells with human gamma-interferon gene via retroviral vector. Cancer Gene Ther 1996; 3:143-150.
39. An DS, Qin FX, Auyeung VC et al. Optimization and functional effects of stable short hairpin RNA expression in primary human lymphocytes via lentiviral vectors. Mol Ther 2006; 14:494-504.
40. Chung J, Scherer LJ, Gu A et al. Optimized lentiviral vectors for HIV gene therapy: Multiplexed expression of small RNAs and inclusion of MGMT(P140K) drug resistance gene. Mol Ther 2014;22:952-963.
41. Amirache F, Lévy C, Costa C et al. Mystery solved: VSV-G-LVs do not allow efficient gene transfer into unstimulated T cells, B cells, and HSCs because they lack the LDL receptor. Blood 2014;123:1422-1424.
42. Zhang H, Berel D, Wang Y et al. A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models. PLoS One 2013;8:e54918.
43. Gaspar HB, Bjorkegren E, Parsley K et al. Successful reconstitution of immunity in ADASCID by stem cell gene therapy following cessation of PEG-ADA and use ofmild preconditioning. Mol Ther 2006;14:505-513.